

Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice

Masamitsu Yanada, Tetsuhito Kojima, Kazuhiro Ishiguro, Yukiko Nakayama, Koji Yamamoto, Tadashi Matsushita, Kenji Kadomatsu, Masahiko Nishimura, Takashi Muramatsu, and Hidehiko Saito

Antithrombin (AT) deficiency is an autosomal disorder associated with venous thromboembolism. However, a diagnosis of homozygous AT deficiency is seldom made. Most patients are heterozygous and have approximately 50% AT activities, and they are at higher risk for the development of thromboembolism. Through gene targeting we generated AT-deficient mice and previously reported that completely AT-deficient mice could not survive the prenatal period because of extensive thrombosis in the myocardium and liver sinusoids. In contrast, heterozygous AT-deficient mice with 50% AT activities have not shown spontane-

ous thromboembolic episodes. To demonstrate a thrombotic tendency in heterozygous AT deficiency, we challenged heterozygous AT-deficient mice (*AT+/-* mice) with the administration of lipopolysaccharide (LPS) or with restraint stress by immobilization. LPS injection markedly induced fibrin deposition in the kidney glomeruli, myocardium, and liver sinusoids in *AT+/-* mice compared with wild-type mice (*AT+/+* mice). Restraint stress tests were performed by placing mice in 50-mL conical centrifuge tubes for 20 hours. Fibrin deposition was observed in the kidney of *AT+/+* and *AT+/-* mice, but *AT+/-* mice exhibited more

extensive fibrin deposition than *AT+/+* mice. After prophylactic administration of human AT concentrates to increase plasma AT activities of *AT+/-* mice, LPS-induced fibrin deposition was effectively prevented. These results suggest that heterozygous AT deficiency is significantly associated with a tendency toward thrombosis formation in the kidney. The *AT+/-* mouse thus is a useful model for studying the effect of environmental or genetic risk factors on thrombogenesis. (Blood. 2002;99:2455-2458)

© 2002 by The American Society of Hematology

Introduction

Antithrombin (AT) is a plasma glycoprotein with a molecular weight of 58 000. It is one of the most important inhibitors of blood coagulation, and it inactivates thrombin and several serine proteases, including factors IXa, Xa, Xia, and XIIa, by forming a 1:1 molar complex between the active site of the serine protease and its reactive site. Heparin has an accelerating effect on the formation of AT–protease complexes. In the presence of heparin, the active site of the protease is brought into close contact with the reactive site of AT, and the rate of inhibition is enhanced up to several thousand times.¹⁻⁴

Congenital AT deficiency is an autosomal disorder associated with venous thromboembolism. The mean prevalence of venous thromboembolism among heterozygous subjects was 51% compared with controls without the deficiency (1.5%).⁵ The incidence of the disorder in the general population is estimated at 1 in 2000 to 5000.^{6,7} AT deficiency is classified into 2 types. Type 1 is a quantitative deficiency, and AT antigens and activities are lowered. Type 2 is a qualitative defect without reduction of AT antigens.^{2,8} Patients with undetectable AT activities or antigens appear to have homozygous AT deficiency, but homozygous AT deficiency is extremely rare. Such patients have been reported to have severe thrombotic diseases of early onset.⁹ Most patients with AT deficiency are heterozygous, and AT activity is approximately half the normal level. Previous population studies had indicated that heterozygous

patients were expected to live as long as the general population in spite of the greater risk for thromboembolic episodes.^{10,11}

We generated congenitally AT-deficient mice through gene targeting and reported that completely AT-deficient mice could not survive the prenatal period because of extensive thrombosis in the myocardium and liver sinusoids along with massive bleeding.¹² In contrast, heterozygous AT-deficient mice (*AT+/-* mice) were born normally, and their external appearance was similar to that of wild-type mice (*AT+/+* mice).¹² To further investigate the role of AT and the impact of its deficiency on the tendency toward thrombosis, we induced a hypercoagulable state by lipopolysaccharide (LPS) challenge and by restraint stress with immobilization in *AT+/-* mice. Purified human AT was tested for the prevention of thrombosis in LPS-challenged *AT+/-* mice, and the requirement of AT for the treatment of the kidney thrombosis was examined.

Materials and methods

Mice

The generation of AT-deficient mice was described previously.¹² In brief, the region including exon 2 of the *AT* gene was replaced by homologous recombination with plasmid *MCIneo* containing *DTA* (diphtheria toxin

From the First Department of Internal Medicine, Department of Biochemistry, and Institute for Laboratory Animal Research, Nagoya University School of Medicine, and the Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya National Hospital, Japan.

Submitted October 11, 2001; accepted November 27, 2001.

Supported in part by Grants-in-Aid for Scientific Research (11470209 and 13470203) from Ministry of Education, Science, Sports and Culture, Center of Excellence Research (COE), and Welfide Medicinal Research Foundation (H.S.).

Reprints: Hidehiko Saito, First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan; e-mail: hsaito@med.nagoya-u.ac.jp.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

fragment A gene) and the *AT* gene fragments cloned from the genomic DNA library of 129SV mice. Male chimeric mice were mated with wild-type C57BL/6J female mice (CLEA, Tokyo, Japan). Littermates of 6-month-old mice were used for thrombogenic challenges. For each genotype, sex and weight were matched for all the experiments in this study. Experimental designs and protocols, including plasmid construction, generation of gene-targeting mice, and thrombogenic challenges, were reviewed by the Nagoya University Animal Research Committee.

Assays for antithrombin

Blood samples were collected into 3.8% sodium citrate at a ratio of 9:1 and were centrifuged at 2000g for 10 minutes to obtain plasma. The plasma was stored at -80°C until assay. Plasma AT antigen levels were determined using N-assay TIA AT-III (Nittobo, Tokyo, Japan), a turbidimetric immunoassay for the antigen-antibody complex. AT activities were measured using N-test ATIII-S (Nittobo), which determines anticoagulant activity using a chromogenic substrate, according to the manufacturer's instructions.

Thrombogenic challenge

Mice were injected intraperitoneally with 5 mg/kg LPS (*Escherichia coli* serotype O111: B4; Sigma, St Louis, MO). Four hours later, mice were killed and the lungs, livers, hearts, and kidneys were removed and fixed overnight in Carnoy solution (methanol:chloroform:acetic acid, 6:3:1). For the rescue experiment of thrombotic disease, *AT*^{+/-} mice were injected through the tail vein with AT concentrates purified from human plasma (Welfide, Osaka, Japan) at doses of 50 U/kg or with physiological saline 30 minutes before LPS challenge.

In another experiment, mice were exposed to restraint stress by placement in 50-mL conical centrifuge tubes in which they could hardly move (Yamamoto et al, manuscript submitted). Air and water were supplied through small punctures in the tube walls. After 20 hours, the mice were killed, and their organs were removed and used for immunohistochemical analysis.

Immunohistochemical analysis

Fixed tissues were dehydrated, embedded in paraffin, and sectioned (6 μm thick). Tissue sections were deparaffinized in xylene, transferred to 100% ethanol, and incubated for 30 minutes in 0.3% hydrogen peroxide-methanol. After rinsing with phosphate-buffered saline (PBS), the slides were incubated successively with 5% normal goat serum-PBS (20 minutes, room temperature), rabbit anti-human fibrin-fibrinogen antibody (DAKO, Glostrup, Denmark) (1:100 dilution, 1 hour, room temperature), anti-rabbit IgG antibody conjugated with biotin (1:500 dilution, 1 hour, room temperature), and avidin-biotin complex conjugated with horseradish peroxidase (Vector Laboratories, Burlingame, CA) (30 minutes, room temperature). Staining was visualized with diaminobenzidine tetrahydrochloride- Ni^{3+} , Co^{2+} (Amersham Pharmacia Biotech, Piscataway, NJ). The percentage of the glomeruli with fibrin deposition (%GFD) was calculated in all areas of each histologic specimen of the kidney. Partially stained glomeruli were categorized as positive (Figure 2A).

Statistical analysis

Stat-View 4.5 (SAS Institute, Cary, NC) was used for statistical analysis. *P* values were calculated using the Student *t* test, and *P* = .05 was considered statistically significant. Data represented means \pm SD.

Genotype determination of *AT*^{+/-} pups

Genomic DNA was extracted from tails of mice as previously described¹² and was used for polymerase chain reaction (PCR) analysis. PCR was performed using the external primers of the replaced gene fragment. The wild-type allele and the mutant allele gave different band sizes. Primer sequences and PCR conditions have been described.¹²

Results

Genotypes and plasma AT levels of *AT*^{+/-} mice

One hundred forty-one pups were born from 20 pairings of *AT*^{+/-} and *AT*^{+/+} mice, and the genotypes were determined by PCR analysis. All 141 pups grew normally; 66 pups were *AT*^{+/-}, and 75 were *AT*^{+/+}. There was no deviation between the 2 genotypes, indicating that the *AT*^{+/-} genotype does not cause embryonic lethality (Figure 1A). The external appearance of *AT*^{+/-} mice could not be distinguished from that of *AT*^{+/+} mice. No spontaneous thromboembolic episodes were observed during the longest follow-up period of 14 months. In humans, pregnant women are at risk for thrombotic disease, but no *AT*^{+/-} female mice developed thrombosis during gestation.

Plasma levels of AT antigens and activities were determined for 8 *AT*^{+/-} mice and 8 *AT*^{+/+} mice. Mean values of antigens and activities for *AT*^{+/-} mice were 8.4 mg/dL and 52.6%, respectively, whereas those for *AT*^{+/+} mice were 13.8 mg/dL and 95.1% (Figure 1B,C). Compared to *AT*^{+/+} mice, mean relative values for AT antigens and activities were 60.9% and 55.3% of *AT*^{+/+} mice, respectively; both values were significantly decreased in *AT*^{+/-} mice (*P* < .01; Figure 1B,C). Hence, the *AT*^{+/-} mice have a heterozygous AT deficiency that would be a risk factor for thrombosis in humans.

Lipopolysaccharide challenge of *AT*^{+/-} mice

Through immunohistochemical analysis, fibrin deposition was detected in the glomeruli and in the peritubular capillaries of the kidney of *AT*^{+/-} mice that were intraperitoneally injected with 5 mg/kg LPS (Figure 2A). Fibrin deposition was also detected in the liver sinusoids (Figure 2B) and small vessels of the myocardium (Figure 2C). We previously found that the *AT*^{-/-} fetus developed degeneration of the myocardium and liver from extensive fibrin deposition,¹² but it did not occur in *AT*^{+/-} mice. In the lung, no fibrin deposition was observed (Figure 2D). Fibrin deposition in the kidney, liver, and myocardium was also observed in *AT*^{+/+} mice after LPS challenge, but their levels were lower than those of *AT*^{+/-} mice (data not shown). All mice survived after LPS administration.

To compare the degree of fibrin deposition in the kidney, we determined the %GFD and compared it between *AT*^{+/-} and *AT*^{+/+} mice (Figure 3). The %GFD was higher in *AT*^{+/-} mice than in *AT*^{+/+} mice (39.8% \pm 14.6% vs 19.7% \pm 10.3%). Student *t* test revealed that the difference was statistically significant (*P* < .01, Figure 3A). As a control, we also examined the kidneys of *AT*^{+/-} mice not challenged with LPS, but no fibrin deposition was observed (data not shown).

Restraint stress

It has been reported that mental or physical stress may affect coagulation level or fibrinolytic factors.^{13,14} Our preliminary observations suggest





Figure 1. Genotype of newborn pups and plasma levels of AT antigens and activities. (A) Genotype of newborn mice from the pairing of *AT*^{+/-} and *AT*^{+/+} mice. One hundred forty-one pups were born from 20 pairings, and the genotypes were determined by PCR analysis. Plasma levels of AT antigens (B) and activities (C) are measured as described in "Materials and methods." AT antigens and activities were significantly reduced in *AT*^{+/-} mice compared with *AT*^{+/+} mice (*n* = 8; *P* < .01). Values are means \pm SD.

Figure 2. Microscopic findings in *AT*^{+/-} mice after LPS challenge. Immunohistochemical staining with anti-fibrin-fibrinogen antibody of the kidney (A), liver (B), heart (C), and lung (D) of *AT*^{+/-} mice. Fibrin deposition was detected in the kidney glomeruli (A), liver sinusoids (B), and small vessels of the myocardium (C). Almost no deposition was observed in the lung (D). Magnifications, $\times 400$ (A-C), $\times 100$ (D).



that restraint stress is a risk factor for thrombosis (Yamamoto et al, manuscript submitted), and we restrained *AT*^{+/+} and *AT*^{+/-} mice by placing them in narrow centrifuge tubes for 20 hours. Figure 3B indicates that the %GFD was significantly higher in *AT*^{+/-} mice than in *AT*^{+/+} mice ($28.1\% \pm 11.4\%$ vs $14.9\% \pm 7.1\%$, $n = 8$, $P < .05$).

AT supplementation before lipopolysaccharide challenge

Next we studied whether AT supplementation before LPS challenge could rescue the kidney thrombus formation in *AT*^{+/-} mice. To determine the appropriate dosage to which to increase plasma AT activities, human AT concentrates were intravenously administered to *AT*^{+/-} mice at doses of 0, 25, 50, 100, and 250 U/kg. Thirty minutes later, plasma levels of AT activities were measured, and the mean levels were 46.7%, 73.9%, 103.6%, 152.4%, and 261.5%, respectively ($n = 3$). Thus we chose 50 U/kg AT concentrates to normalize plasma AT levels of *AT*^{+/-} mice.

The same volume of human AT concentrates or physiological saline was injected into the tail veins of *AT*^{+/-} mice 30 minutes before LPS challenge. Prophylactic AT treatment significantly

reduced the %GFD ($28.5\% \pm 12.4\%$ for AT supplementation vs $40.8\% \pm 14.8\%$ for saline; $P < .05$, Figure 4). The improved %GFD (28.5%) was, however, slightly higher than that of the LPS-challenged *AT*^{+/+} mice without AT supplementation (19.7% , Figure 3A), though the difference was not significant ($P = .07$), suggesting the possibility that supplemented AT was not enough to suppress LPS-induced thrombus formation completely.

Discussion

During our 14-month observation period, no heterozygous AT-deficient mice developed spontaneous thrombotic disease. In patients with heterozygous AT deficiency, decreased plasma AT levels may not be the absolute risk factor for thrombosis but may play an additional and important role with other risk factors.^{3,15} In most instances, thromboembolic episodes of such patients are associated with acquired conditions, including acute infection, surgery, pregnancy, delivery, major trauma, and the use of oral contraceptives.¹⁵ Other genetic risk factors such as factor V Leiden also predispose to the development of thrombosis in heterozygous AT-deficient subjects.¹⁶

LPS or endotoxin is the specific cell membrane component of microorganisms, and it triggers the activation of the coagulation cascade.¹⁷ We induced a hypercoagulable state in *AT*^{+/-} mice by LPS




Figure 3. Percentage of glomeruli with fibrin deposition (%GFD) in *AT*^{+/+} and *AT*^{+/-} mice. (A) The %GFD of *AT*^{+/+} mice and *AT*^{+/-} mice after LPS challenge. LPS was intraperitoneally injected into mice as described in "Materials and methods." After 4 hours, kidney specimens were subjected to immunohistochemical analysis as described in the legend to Figure 2. The %GFD was significantly higher in *AT*^{+/-} mice than in *AT*^{+/+} mice ($n = 12$, $P < .01$). (B) The %GFD of *AT*^{+/+} mice and *AT*^{+/-} mice after exposure to restraint stress. Mice were placed in 50-mL tubes for 20 hours with appropriate water and air supply. The %GFD was significantly higher in *AT*^{+/-} mice than in *AT*^{+/+} mice ($n = 8$; $P < .05$). Values are means \pm SD.




Figure 4. Effect of AT supplementation before LPS challenge to *AT*^{+/-} mice. Prophylactic AT treatment was performed 4 hours before LPS challenge using 50 U/kg human AT concentrates (AT) as described in "Materials and methods." The same volume of control physiological saline was injected. AT supplementation significantly reduced %GFD of *AT*^{+/-} mice ($n = 12$; $P < .05$). Values are means \pm SD.

challenge and demonstrated that AT deficiency was strongly associated with fibrin deposition in glomeruli of the kidney (Figure 3A). Normalizing AT levels by the purified human AT concentrates before LPS challenge significantly reduced fibrin deposition (Figure 4). These facts indicate that fibrin deposition in the kidney of *AT+/-* mice is attributed to decreased AT levels and that heterozygous AT deficiency is a risk factor for renal thrombosis. Although patients with heterozygous AT deficiency have deep vein thrombosis, no *AT+/-* mice exhibited the thrombotic disease in hands or feet. Mice harboring the factor V Leiden mutation have thrombosis in the lower limbs, but this phenotype is reported to be rare.¹⁸ Such differences in disease phenotype between humans and mice may not be interpreted by this study, and further observations may be required to study the blood flow in arms and legs of mice.

Systemic infectious diseases occasionally lead to the release of endotoxin, a major thrombogenic agent. Indeed, thromboembolic episodes of patients with heterozygous AT deficiency are reported to be associated occasionally with acute infection,¹⁵ suggesting that patients with heterozygous AT deficiency are susceptible to endotoxin-induced hypercoagulation. Our experiment clearly indicated that prophylactic AT supplementation successfully rescued the thrombotic kidney disease of *AT+/-* mice (Figure 4), suggesting the therapeutic roles of AT for thrombotic human diseases. A recent randomized control study by Warren et al¹⁹ used high-dose intravenous AT for patients with severe sepsis. Mean baseline AT level before treatment was approximately 60%, and it was increased to 180% 24 hours after AT administration. However, AT administration did not significantly improve the mortality rate of patients compared with placebo controls. Taken together, the observed effects on %GFD in *AT+/-* mice might be restricted to diseases caused by AT deficiency.

The improved %GFD achieved by AT supplementation (Figure 4) was still higher than %GFD of *AT+/+* mice (Figure 3A), which were also challenged by LPS without pretreatment (28.5% ± 12.4% vs 19.7% ± 10.3%; *P* = .07). It has been reported that plasma AT levels begin to decrease early in sepsis because of excessive consumption.^{20,21} Indeed, AT activities of *AT+/-* mice 4 hours after LPS challenge were decreased to 63.0%, whereas 30 minutes after AT injection they

measured 103.6%. In *AT+/+* mice, the activity was also decreased to 71.8% 4 hours after LPS challenge, and the decrease was statistically significant. Therefore, AT appeared to be consumed during LPS-induced thrombin generation. Dose escalation of administered AT may be required to rescue the fibrin deposition of *AT+/-* mice with the comparable level of *AT+/+* mice without pretreatment.

Mental or physical stress appears to affect plasma coagulation and fibrinolysis. In humans, it is one of the triggers of unstable angina, myocardial infarction, and sudden death.²²⁻²⁴ The levels of several coagulation or fibrinolytic factors—including von Willebrand factor, factor VIII, factor VII,¹³ or plasminogen activator inhibitor-1 (PAI-1)¹⁴—appear to increase in response to mental stress, suggesting the possibility that prothrombotic potential may be increased, thus promoting thrombotic complications under stressful conditions. In this study, as an alternative thrombogenic challenge, we exposed *AT+/+* and *AT+/-* mice to 20 hours of restraint stress. *AT+/-* mice developed renal thrombosis to a greater degree than did *AT+/+* mice (Figure 3B), indicating that heterozygous AT-deficient mice are susceptible to stress-induced renal thrombosis. In our preliminary observation, restraint stress increased PAI-1 expression in the kidney glomerulus (Yamamoto et al, manuscript submitted). Presumably, the thrombogenic risk for AT-deficient mice might be increased by the lower fibrinolytic potential.

In this study, we confirmed that congenital heterozygous AT deficiency is associated with a tendency to thrombosis as well as complete AT deficiency, but these disorders are not identical in pathophysiology. *AT+/-* mice are at risk for thrombosis, but additional thrombogenic stimulations are required. The addition of other genetic risk factors into the *AT+/-* genotype will provide further understanding of the role of AT in thrombogenesis.

Acknowledgments

We thank Takayuki Nakayama and Kyosuke Takeshita for their helpful advice and discussions. We greatly thank Kazuo Kagami, Kayo Sakakura, and Eriko Yamafuji for their technical assistance.

References

- Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. *Semin Hematol*. 1991;28:10-18.
- Blajchman MA, Austin RC, Fernandez-Rachubinski F, Sheffield WP. Molecular basis of inherited human antithrombin deficiency. *Blood*. 1992;80:2159-2171.
- van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. *Semin Hematol*. 1997;34:188-204.
- Pratt CW, Church FC. Antithrombin: structure and function. *Semin Hematol*. 1991;28:3-9.
- Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin III-deficient persons: report of a large kindred and literature review. *Ann Intern Med*. 1992;116:754-761.
- Rosenberg RD. Actions and interactions of antithrombin and heparin. *N Engl J Med*. 1975;292:146-151.
- Abildgaard U. Antithrombin and related inhibitors of coagulation. In: Poller L. *Recent Advances in Blood Coagulation*. Edinburgh, Scotland: Churchill Livingstone; 1981:151-175.
- Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. *Thromb Haemost*. 1997;78:339-343.
- Chowdhury V, Lane DA, Mille B, et al. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. *Thromb Haemost*. 1994;72:198-202.
- Rosendaal FR, Heijboer H, Briet E, et al. Mortality in hereditary antithrombin-III deficiency: 1830 to 1989. *Lancet*. 1991;337:260-262.
- van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR. Mortality and cause of death in inherited antithrombin deficiency. *Thromb Haemost*. 1997;77:452-455.
- Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. *J Clin Invest*. 2000;106:873-878.
- Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. *Thromb Haemost*. 1989;62:767-771.
- Wojta J, Holzer M, Hufnagl P, Christ G, Hoover RL, Binder BR. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. *Am J Pathol*. 1991;139:911-919.
- Menache D. Replacement therapy in patients with hereditary antithrombin III deficiency. *Semin Hematol*. 1991;28:31-38.
- van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. *Thromb Haemost*. 1996;75:417-421.
- Levi M, ten Cate H. Disseminated intravascular coagulation. *N Engl J Med*. 1999;341:586-592.
- Cui J, Eitzman DT, Westric RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. *Blood*. 2000;96:4222-4226.
- Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: a randomized control trial. *JAMA*. 2001;286:1869-1878.
- Bick RL, Dukes ML, Wilson WL, Fekete LF. Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulation. *Thromb Res*. 1977;10:721-729.
- Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with *Escherichia coli*. *Blood*. 2000;95:1117-1123.
- Ciampricotti R, el Gamal MI. Unstable angina, myocardial infarction and sudden death after an exercise stress test. *Int J Cardiol*. 1989;24:211-218.
- Lecomte D, Fornes P, Nicolas G. Stressful events as a trigger of sudden death: a study of 43 medico-legal autopsy cases. *Forensic Sci Int*. 1996;79:1-10.
- Matsuo T, Suzuki S, Kodama K, Kario K. Hemostatic activation and cardiac events after the 1995 Hanshin-Awaji earthquake. *Int J Hematol*. 1998;67:123-129.